 MARLBOROUGH, Mass., Sept. 30, 2021 PRNewswire -- Phio Pharmaceuticals Corp. Nasdaq: PHIO, a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi INTASYLTM therapeutic platform, today announced two poster presentations at upcoming scientific conferences scheduled to take place in October 2021. 